Cargando…

Measurement Reproducibility in the Early Stages of Biomarker Development

Biomarker discovery and development requires measurement reproducibility studies in addition to case-control studies. Parallel pursuit of reproducibility studies is especially important for emerging technologies such as protein biomarkers based on time-of-flight mass spectrometry, the case considere...

Descripción completa

Detalles Bibliográficos
Autores principales: Liggett, Walter S., Barker, Peter E., Semmes, O. John, Cazares, Lisa H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839328/
https://www.ncbi.nlm.nih.gov/pubmed/15665389
http://dx.doi.org/10.1155/2004/726517
_version_ 1782478422954475520
author Liggett, Walter S.
Barker, Peter E.
Semmes, O. John
Cazares, Lisa H.
author_facet Liggett, Walter S.
Barker, Peter E.
Semmes, O. John
Cazares, Lisa H.
author_sort Liggett, Walter S.
collection PubMed
description Biomarker discovery and development requires measurement reproducibility studies in addition to case-control studies. Parallel pursuit of reproducibility studies is especially important for emerging technologies such as protein biomarkers based on time-of-flight mass spectrometry, the case considered in this paper. For parallel studies, a way to improve reproducibility prior to identification of protein species is necessary. One approach is use of functional principal components analysis (PCA) as the basis for assessing measurement reproducibility. Reproducibility studies involve repeated measurement of a reference material such as a human serum standard. Measurement in our example is by SELDI-TOF (surface-enhanced laser desorption and ionization time-of-flight) mass spectrometry. Reproducibility is defined in reference to a source of variation, which in our example is associated with a type of commercially available protein biochip. We obtained spectra for 8 spots on each 11 chips. Two spectra are generally more alike when obtained from the same chip rather than different chips. Thus, our experiment indicates potential improvements from reducing variation in chip manufacture and chip handling during measurement. Our analysis involves careful registration of the spectra and characterization of the spectral differences. As shown by our example, a metrological analysis may enhance case-control studies by guiding optimization of the measurements underlying the biomarker.
format Online
Article
Text
id pubmed-3839328
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-38393282013-12-17 Measurement Reproducibility in the Early Stages of Biomarker Development Liggett, Walter S. Barker, Peter E. Semmes, O. John Cazares, Lisa H. Dis Markers Other Biomarker discovery and development requires measurement reproducibility studies in addition to case-control studies. Parallel pursuit of reproducibility studies is especially important for emerging technologies such as protein biomarkers based on time-of-flight mass spectrometry, the case considered in this paper. For parallel studies, a way to improve reproducibility prior to identification of protein species is necessary. One approach is use of functional principal components analysis (PCA) as the basis for assessing measurement reproducibility. Reproducibility studies involve repeated measurement of a reference material such as a human serum standard. Measurement in our example is by SELDI-TOF (surface-enhanced laser desorption and ionization time-of-flight) mass spectrometry. Reproducibility is defined in reference to a source of variation, which in our example is associated with a type of commercially available protein biochip. We obtained spectra for 8 spots on each 11 chips. Two spectra are generally more alike when obtained from the same chip rather than different chips. Thus, our experiment indicates potential improvements from reducing variation in chip manufacture and chip handling during measurement. Our analysis involves careful registration of the spectra and characterization of the spectral differences. As shown by our example, a metrological analysis may enhance case-control studies by guiding optimization of the measurements underlying the biomarker. IOS Press 2004 2005-01-18 /pmc/articles/PMC3839328/ /pubmed/15665389 http://dx.doi.org/10.1155/2004/726517 Text en Copyright © 2004 Hindawi Publishing Corporation.
spellingShingle Other
Liggett, Walter S.
Barker, Peter E.
Semmes, O. John
Cazares, Lisa H.
Measurement Reproducibility in the Early Stages of Biomarker Development
title Measurement Reproducibility in the Early Stages of Biomarker Development
title_full Measurement Reproducibility in the Early Stages of Biomarker Development
title_fullStr Measurement Reproducibility in the Early Stages of Biomarker Development
title_full_unstemmed Measurement Reproducibility in the Early Stages of Biomarker Development
title_short Measurement Reproducibility in the Early Stages of Biomarker Development
title_sort measurement reproducibility in the early stages of biomarker development
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839328/
https://www.ncbi.nlm.nih.gov/pubmed/15665389
http://dx.doi.org/10.1155/2004/726517
work_keys_str_mv AT liggettwalters measurementreproducibilityintheearlystagesofbiomarkerdevelopment
AT barkerpetere measurementreproducibilityintheearlystagesofbiomarkerdevelopment
AT semmesojohn measurementreproducibilityintheearlystagesofbiomarkerdevelopment
AT cazareslisah measurementreproducibilityintheearlystagesofbiomarkerdevelopment